Physician profile
Michael S Marcus
NPI 1942291836
$403.62
in general payments reported to CMS, 2019-2025
10 companies · $51.53 in 2025
The $51.53 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.57 · 2020: $83.89 · 2021: $72.44 · 2022: $101 · 2023: $15.00 · 2024: $21.35 · 2025: $51.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $143.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.52 | 2019-2024 | Bridion |
| Edwards Lifesciences Corporation | $59.67 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $30.97 | 2020 | |
| Csl Behring | $25.21 | 2022 | |
| Boston Scientific Corporation | $19.87 | 2025 | Enroute Transcarotid Neuroprotection System |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2023 | Trulance |
| Acelrx Pharmaceuticals, INC. | $14.94 | 2019 | |
| Karl Storz Endoscopy-America | $14.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.